George Zogopoulos
Overview
Explore the profile of George Zogopoulos including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
63
Citations
2915
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nickerson J, Cyr C, Arseneau R, Lee S, Condon-Oldreive S, Zogopoulos G, et al.
Curr Oncol
. 2024 Oct;
31(10):6191-6204.
PMID: 39451765
Pancreatic cancer is a complex malignancy associated with poor prognosis and high symptom burden. Optimal patient care relies on the integration of various sectors in the healthcare field as well...
2.
Zogopoulos G, Haimi I, Sanoba S, Everett J, Wang Y, Katona B, et al.
J Natl Compr Canc Netw
. 2024 Apr;
22(3):158-166.
PMID: 38626807
Background: Pancreatic adenocarcinoma (PC) is a highly lethal malignancy with a survival rate of only 12%. Surveillance is recommended for high-risk individuals (HRIs), but it is not widely adopted. To...
3.
Pervin J, Asad M, Cao S, Jang G, Feizi N, Haibe-Kains B, et al.
Front Genet
. 2023 Nov;
14:1282824.
PMID: 38028629
Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease characterized by a diverse tumor microenvironment. The heterogeneous cellular composition of PDAC makes it challenging to study molecular features of tumor cells...
4.
Romero J, Titmuss E, Wang Y, Vafiadis J, Pacis A, Jang G, et al.
NPJ Precis Oncol
. 2023 Aug;
7(1):73.
PMID: 37558751
Immune checkpoint inhibitors (ICI) are highly effective in specific cancers where canonical markers of antitumor immunity are used for patient selection. Improved predictors of T cell-inflammation are needed to identify...
5.
Chen Y, Sahai A, Donatelli G, Lam E, Forbes N, Mosko J, et al.
Gastroenterology
. 2023 Aug;
165(5):1249-1261.e5.
PMID: 37549753
Background & Aims: Endoscopic ultrasound-guided choledochoduodenostomy with a lumen-apposing metal stent (EUS-CDS) is a promising modality for management of malignant distal biliary obstruction (MDBO) with potential for better stent patency....
6.
Katona B, Klute K, Brand R, Everett J, Farrell J, Hawthorne K, et al.
Cancer Prev Res (Phila)
. 2023 Jun;
16(6):343-352.
PMID: 37259800
Prevention Relevance: Pancreatic cancer surveillance is critical to decreasing pancreatic cancer mortality; therefore, it is important that pancreatic cancer surveillance studies enroll diverse patients. We demonstrate that substantial racial/ethnic- and...
7.
Sorin M, Camilleri-Broet S, Pichette E, Lorange J, Haghandish N, Dube L, et al.
Cancer Treat Res Commun
. 2023 Mar;
35:100696.
PMID: 36958133
Background: Lung cancer is the leading cause of cancer death in both men and women. Quebec has the highest lung cancer mortality out of all provinces in Canada, believed to...
8.
Ma L, Wang Y, Espin-Garcia O, Allen M, Jang G, Zhang A, et al.
Br J Cancer
. 2023 Mar;
128(10):1916-1921.
PMID: 36927977
Background: Systemic inflammatory scores may aid prognostication and patient selection for trials. We compared five scores in advanced pancreatic adenocarcinoma (PDAC). Methods: Unresectable/metastatic PDAC patients enrolled in the Comprehensive Molecular...
9.
Perera S, Jang G, Wang Y, Kelly D, Allen M, Zhang A, et al.
Clin Cancer Res
. 2022 Oct;
28(23):5115-5120.
PMID: 36222851
Purpose: Modified FOLFIRINOX (mFFX) and gemcitabine/nab-paclitaxel (GnP) remain standard first-line options for patients with advanced pancreatic ductal adenocarcinoma (PDAC). Human equilibrative nucleoside transporter 1 (hENT1) was hypothesized to be a...
10.
Dankner M, Wang Y, Fazelzad R, Johnson B, Nebhan C, Dagogo-Jack I, et al.
JCO Precis Oncol
. 2022 Aug;
6:e2200107.
PMID: 35977349
Purpose: Non-V600 mutations comprise approximately 35% of all BRAF mutations in cancer. Many of these mutations have been identified as oncogenic drivers and can be classified into three classes according...